Globus MedicalGMED
About: Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.
Employees: 5,000
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
300% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $3.38M
2% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 53
1% less funds holding
Funds holding: 446 [Q2] → 442 (-4) [Q3]
2% less capital invested
Capital invested by funds: $7.95B [Q2] → $7.79B (-$162M) [Q3]
6.72% less ownership
Funds ownership: 103.1% [Q2] → 96.39% (-6.72%) [Q3]
17% less repeat investments, than reductions
Existing positions increased: 144 | Existing positions reduced: 174
18% less funds holding in top 10
Funds holding in top 10: 22 [Q2] → 18 (-4) [Q3]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
10 analyst ratings
Canaccord Genuity William Plovanic 72% 1-year accuracy 34 / 47 met price target | 11%upside $101 | Buy Maintained | 10 Jan 2025 |
B of A Securities Craig Bijou 57% 1-year accuracy 4 / 7 met price target | 7%upside $97 | Neutral Upgraded | 9 Jan 2025 |
Truist Securities Richard Newitter 79% 1-year accuracy 33 / 42 met price target | 1%downside $90 | Hold Maintained | 18 Dec 2024 |
Roth MKM Jason Wittes 63% 1-year accuracy 12 / 19 met price target | 27%upside $115 | Buy Maintained | 17 Dec 2024 |
BTIG Ryan Zimmerman 68% 1-year accuracy 32 / 47 met price target | 0%upside $91 | Buy Maintained | 12 Dec 2024 |
Financial journalist opinion
Based on 10 articles about GMED published over the past 30 days
